Arvinas reported Phase 1 multiple‑dose data for ARV‑102, a PROTAC degrader targeting LRRK2, showing approximately ≥50% reduction of LRRK2 protein in cerebrospinal fluid by day 14 that was sustained through day 28. The single‑center, randomized, placebo‑controlled multiple‑dose cohort—doses 20–80 mg daily—demonstrated dose‑dependent CSF exposure and reduction of endolysosomal and neuroinflammatory biomarkers, supporting central target engagement and brain penetration. Data were presented orally at AD/PD 2026 in Copenhagen. Arvinas said ARV‑102 was well tolerated across doses, and the company indicated these results support further development in Parkinson’s disease and related lysosomal dysfunction disorders.